By Newsbreak Producer Genevieve Lanka - As phase two of the Pfizer COVID-19 clinical trial for children aged five to eleven shows favourable results, parents are faced with a critical decision on whether or not to vaccinate. The pharmaceutical giant says latest trial results have shown that the vaccine was well tolerated and generated a robust antibody response in this younger age group. While some parents have welcomed the results, others are a little sceptical. Genevieve Lanka spoke to several parents and filed this report...